moomoo ID:0
Log Out
  • English
  • 中文繁体
  • 中文简体

Talaris Therapeutics, Inc. (NASDAQ:TALS) Short Interest Up 22.5% in November

kopsource ·  12/02/2022 06:01

Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) saw a large growth in short interest in November. As of November 15th, there was short interest totalling 703,800 shares, a growth of 22.5% from the October 31st total of 574,700 shares. Based on an average daily trading volume, of 200,500 shares, the short-interest ratio is presently 3.5 days. Approximately 3.6% of the shares of the stock are sold short.

Hedge Funds Weigh In On Talaris Therapeutics

A number of hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC bought a new stake in Talaris Therapeutics during the 3rd quarter worth approximately $27,000. Amalgamated Bank bought a new stake in Talaris Therapeutics during the 1st quarter worth approximately $31,000. Commonwealth Equity Services LLC bought a new position in Talaris Therapeutics in the 3rd quarter valued at $34,000. Prospera Financial Services Inc bought a new position in Talaris Therapeutics in the 3rd quarter valued at $34,000. Finally, Values First Advisors Inc. bought a new position in Talaris Therapeutics in the 2nd quarter valued at $53,000. 67.99% of the stock is owned by institutional investors and hedge funds.

Get Talaris Therapeutics alerts:

Talaris Therapeutics Price Performance

Shares of NASDAQ TALS traded down $0.03 during trading hours on Thursday, hitting $1.43. 1,395 shares of the company's stock were exchanged, compared to its average volume of 141,180. Talaris Therapeutics has a 1-year low of $1.16 and a 1-year high of $16.63. The company's 50-day moving average price is $1.91 and its 200-day moving average price is $4.05.

Talaris Therapeutics (NASDAQ:TALS – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Research analysts anticipate that Talaris Therapeutics will post -1.86 EPS for the current year.

Wall Street Analysts Forecast Growth

TALS has been the topic of a number of recent analyst reports. Evercore ISI boosted their target price on Talaris Therapeutics to $20.00 in a research report on Monday, August 15th. Morgan Stanley lowered their price target on Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Friday, September 9th. Finally, HC Wainwright started coverage on Talaris Therapeutics in a report on Thursday, October 20th. They set a "buy" rating and a $18.00 price target on the stock.

Talaris Therapeutics Company Profile

(Get Rating)

Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.

Recommended Stories

  • Get a free copy of the research report on Talaris Therapeutics (TALS)
  • Are the Short Sellers Still Right About Mullen Automotive stock?
  • La-Z-Boy Reclines To More Comfortable Levels
  • Is The Recovery Rally Here For SoFi?
  • Is Apple Going To Rally Into Year End?
  • Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?

Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites and Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.